Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Ascendis Pharma A/S Oncology program update Transcript

May 31, 2023 / 02:00PM GMT
Release Date Price: $86.97 (+1.39%)
Scott T. Smith;S;CFO
Ascendis Pharma A;Executive VP & Member of Executive Board

/- -

Okay. I think we'll get started. Welcome, everyone, in the room and online to Ascendis Pharma's oncology program update. Hopefully, I can get this working.

Here we go. Here on Slide 2, I'm lucky enough to take Tim's part today. I'd remind you that we may make forward-looking comments during this presentation, including statements regarding our TransCon technology platform and our oncology product candidates. Actual results may differ materially from those expressed or implied and you should not place undue reliance on these statements. For information concerning the factors that could cause actual results to differ materially, please see the Risk Factors section of our most recent annual report on Form 20-F.

Turning to Slide 3. We have a great agenda for you this morning. Today, we will focus, in particular, on presenting the monotherapy data used to declare the TransCon IL-2 beta/gamma recommended Phase II dose. These data are an updated data cut compared to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot